CD40-ligand-dependent induction of COX-2 gene expression in endothelial cells by activated platelets: inhibitory effects of atorvastatin

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Blood Coagulation and Fibrinolysis

• Publication date

  2005-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/01.mbc.0000161563.36270.a2PMID 15741797
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation

  2004cited by this paper
• Effect of atorvastatin on the expression of CD40 ligand and P-selectin on platelets in patients with hypercholesterolemia.

  2004cited by this paper
• Effect of Atorvastatin on Risk of Recurrent Cardiovascular Events After an Acute Coronary Syndrome Associated With High Soluble CD40 Ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study

  2004cited by this paper
• Role of platelets in the development of atherosclerosis.

  2004cited by this paper
• Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents?

  2004cited by this paper
• Serial Measurement of Surface Expressions of CD63, P-Selectin and CD40 Ligand on Platelets in Atherosclerotic Ischemic Stroke

  2003cited by this paper
• Platelets, atherosclerosis and the endothelium: new therapeutic targets?

  2003cited by this paper
• Cyclooxygenase Isoforms and Platelet Vessel Wall Interactions in the Apolipoprotein E Knockout Mouse Model of Atherosclerosis

  2003cited by this paper
• Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis.

  2003cited by this paper
• CD40 ligation triggers COX-2 expression in endothelial cells: evidence that CD40-mediated IL-6 synthesis is COX-2-dependent

  2003cited by this paper
• Control of COX-2 and iNOS gene expressions by aspirin and salicylate.

  2003cited by this paper
• The platelet CD40L/GP IIb-IIIa axis in atherothrombotic disease

  2003cited by this paper
• Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation

  2003cited by this paper
• Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy.

  2003cited by this paper
• Selective COX-2 Inhibition Improves Endothelial Function in Coronary Artery Disease

  2003cited by this paper
• Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles.

  2003cited by this paper
• Platelet–CD40 ligand interaction with melanoma cell and monocyte CD40 enhances cellular procoagulant activity

  2002cited by this paper
• Statins as anti-inflammatory agents.

  2002cited by this paper
• 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase-Independent Inhibition of CD40 Expression by Atorvastatin in Human Endothelial Cells

  2002cited by this paper
• High doses of atorvastatin do not affect activity of prothrombinase in patients with acute coronary syndromes

  2002cited by this paper
• Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis.

  2002cited by this paper
• Cyclooxygenase-2 and atherosclerosis

  2002cited by this paper
• Oxidized Low-Density Lipoprotein Augments and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Limit CD40 and CD40L Expression in Human Vascular Cells

  2002cited by this paper
• Rho-GTPase–Dependent Platelet-Neutrophil Interaction Affected by HMG-CoA Reductase Inhibition With Altered Adenosine Nucleotide Release and Function

  2002cited by this paper
• CD40-CD40L interactions in atherosclerosis.

  2002cited by this paper
• Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors.

  2001cited by this paper
• [Statins as Anti-Inflammatory Agents]

  2001cited by this paper
• Platelet-endothelial interactions in atherosclerosis

  2001cited by this paper
• High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease.

  2001cited by this paper
• The CD40/CD154 receptor/ligand dyadRID="†"ID="†" Review

  2001cited by this paper
• CD154 (CD40 ligand).

  2000cited by this paper
• Pharmacodynamics and Pharmacokinetic‐Pharmacodynamic Relationships of Atorvastatin, an HMG‐CoA Reductase Inhibitor

  2000cited by this paper
• Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions.

  1999cited by this paper
• Mechanisms of protection afforded by cyclooxygenase inhibitors to endothelial function against ischemic injury in rat isolated hearts.

  1999cited by this paper
• Regulation of the Thrombotic Potential of Atheroma

  1999cited by this paper
• Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages.

  1999cited by this paper
• Atherosclerosis--an inflammatory disease.

  1999cited by this paper
• CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells

  1998cited by this paper
• Rate of vasoconstrictor prostanoids released by endothelial cells depends on cyclooxygenase-2 expression and prostaglandin I synthase activity.

  1998cited by this paper
• Pharmacodynamic Effects and Pharmacokinetics of Atorvastatin after Administration to Normocholesterolemic Subjects in the Morning and Evening

  1996cited by this paper
• Rate of Vasoconstrictor Prostanoids Released by Endothelial Cells Depends on Cyclooxygenase-2 Expression and Prostaglandin I Synthase Activity Original Contributions

  year unknowncited by this paper

• Impact of statin therapy on CD40:CD40L signaling: mechanistic insights and therapeutic opportunities

  2024cites this paper
• Harnessing Oxylipins and Inflammation Modulation for Prevention and Treatment of Colorectal Cancer

  2024cites this paper
• Statins reduce vascular inflammation in atherogenesis: a review of underlying molecular mechanisms.

  2020cites this paper
• CD40L and TNF both activate the classical NF-κB pathway, which is not required for the CD40L induced alternative pathway in endothelial cells.

  2018cites this paper
• Atorvastatin attenuates the antinociceptive tolerance of morphine via nitric oxide dependent pathway in male mice.

  2016cites this paper
• Relationship between statin type and responsiveness to clopidogrel in patients treated with percutaneous coronary intervention: a subgroup analysis of the CILON-T trial.

  2014cites this paper
• Statins in chronic kidney disease and kidney transplantation.

  2014cites this paper
• Statins and intracerebral hemorrhage

  2014cites this paper
• Translating the effects of statins: From redox regulation to suppression of vascular wall inflammation

  2012cites this paper
• The Involvement of the CD40-CD40L Pathway in Activated Platelet-Induced Changes in HUVEC COX-2 and PPARα Expression

  2012cites this paper
• Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular Mechanisms and Lessons from the Recent Clinical Trials

  2012cites this paper
• Simvastatin and atorvastatin attenuate VCAM-1 and uPAR expression on human endothelial cells and platelet surface expression of CD40 ligand.

  2012cites this paper
• Beneficio clínico de las estatinas: ¿hemos cubierto todo el espectro?

  2011cites this paper
• Functional rs20417 SNP (–765G>C) of Cyclooxygenase-2 Gene Does Not Predict the Risk of Recurrence of Ischemic Events in Coronary Patients: Results of a 7-Year Prospective Study

  2010cites this paper
• The pleiotropic effects of statins and omega-3 fatty acids against sepsis: a new perspective

  2010cites this paper
• Statins May Increase Intracerebral Hemorrhage Volume

  2010cites this paper
• CD40/CD40L signaling and its implication in health and disease

  2009cites this paper
• Rôles physiopathologiques du complément dans le syndrome coronarien aigu et implications thérapeutiques

  2009cites this paper
• Linking Inflammation With Atherothrombosis

  2009cites this paper
• The CD40/CD40 ligand system: linking inflammation with atherothrombosis.

  2009cites this paper
• CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease.

  2008cites this paper
• Premature labor: a state of platelet activation?

  2008cites this paper
• Antioxidant is a useful supportive agent for the treatment of coronary vasospasm with endothelial dysfunction in pig

  2007cites this paper
• Statins Increase Risk of Hemorrhagic Stroke by Inhibition of the PAR-1 Receptor

  2007cites this paper
• The mevalonate pathway as a therapeutic target in the Ph-negative chronic myeloproliferative disorders.

  2007cites this paper
• Platelet inhibition beyond conventional antiplatelet agents: expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors

  2006cites this paper
• Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential?

  2006cites this paper